Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa V Hampson

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Paediatric Anaesthesia|February 25, 2021
Study to evaluate the optimal dose of remifentanil required to ensure apnea during magnetic resonance imaging of the heart under general anesthesiaPhilip Arnold, Syed Sanaulla, Lisa V Hampson, et al.
JCO Precision Oncology|February 1, 2022
Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical TrialsEvgeny Degtyarev, Yiyun Zhang, Kapildeb Sen, et al.
BMJ Open|May 22, 2019
Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcomaCaroline Brard, Sophie Piperno-Neumann, Jessy Delaye, et al.
Clinical Pharmacology and Therapeutics|November 11, 2021
A New Comprehensive Approach to Assess the Probability of Success of Development Programs Before Pivotal TrialsLisa V Hampson, Björn Holzhauer, Björn Bornkamp, et al.
Pharmaceutical Statistics|December 15, 2021
Improving the assessment of the probability of success in late stage drug developmentLisa V Hampson, Björn Bornkamp, Björn Holzhauer, et al.
Statistics in Biopharmaceutical Research|May 26, 2025
Monitoring overall survival in pivotal trials in indolent cancersThomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, et al.
Pharmaceutical Statistics|April 4, 2022
Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case studyBjörn Holzhauer, Lisa V Hampson, John Paul Gosling, et al.
CNS Drugs|September 15, 2016
Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using ExtrapolationIan Wadsworth, Thomas Jaki, Graeme J Sills, et al.
Trials|October 12, 2018
Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA<sup>2</sup> guidanceWilliam Sones, Steven A Julious, Joanne C Rothwell, et al.
Trials|June 14, 2017
Choosing the target difference ('effect size') for a randomised controlled trial - DELTA<sup>2</sup> guidance protocolJonathan A Cook, Steven A Julious, William Sones, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Paediatric Anaesthesia|February 25, 2021
Study to evaluate the optimal dose of remifentanil required to ensure apnea during magnetic resonance imaging of the heart under general anesthesiaPhilip Arnold, Syed Sanaulla, Lisa V Hampson, et al.
JCO Precision Oncology|February 1, 2022
Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical TrialsEvgeny Degtyarev, Yiyun Zhang, Kapildeb Sen, et al.
BMJ Open|May 22, 2019
Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcomaCaroline Brard, Sophie Piperno-Neumann, Jessy Delaye, et al.
Clinical Pharmacology and Therapeutics|November 11, 2021
A New Comprehensive Approach to Assess the Probability of Success of Development Programs Before Pivotal TrialsLisa V Hampson, Björn Holzhauer, Björn Bornkamp, et al.
Pharmaceutical Statistics|December 15, 2021
Improving the assessment of the probability of success in late stage drug developmentLisa V Hampson, Björn Bornkamp, Björn Holzhauer, et al.
Statistics in Biopharmaceutical Research|May 26, 2025
Monitoring overall survival in pivotal trials in indolent cancersThomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, et al.
Pharmaceutical Statistics|April 4, 2022
Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case studyBjörn Holzhauer, Lisa V Hampson, John Paul Gosling, et al.
CNS Drugs|September 15, 2016
Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using ExtrapolationIan Wadsworth, Thomas Jaki, Graeme J Sills, et al.
Trials|October 12, 2018
Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA<sup>2</sup> guidanceWilliam Sones, Steven A Julious, Joanne C Rothwell, et al.
Trials|June 14, 2017
Choosing the target difference ('effect size') for a randomised controlled trial - DELTA<sup>2</sup> guidance protocolJonathan A Cook, Steven A Julious, William Sones, et al.
Pageof 4